Anita Bosak
Overview
Explore the profile of Anita Bosak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kesic J, Popsavin M, Benedekovic G, Kojic V, Bosak A, Matosevic A, et al.
Eur J Med Chem
. 2025 Feb;
287:117326.
PMID: 39892092
Herein, the modified synthesis of natural lactone (-)-cleistanolate (1) and its enantiomer (ent-1), along with the synthesis of six new analogues (3, 10, 11, 12, 13, ent-3), is presented. The...
2.
Bartolic M, Matosevic A, Marakovic N, Busic V, Roca S, Vikic-Topic D, et al.
J Enzyme Inhib Med Chem
. 2024 Dec;
39(1):2431832.
PMID: 39654394
The growing prevalence of Alzheimer's disease calls for a drug that can simultaneously act towards several targets involved in the pathophysiology of the disease. In our study, we evaluated the...
3.
Matosevic A, Opsenica D, Bartolic M, Marakovic N, Stoilkovic A, Komatovic K, et al.
Molecules
. 2024 Nov;
29(22).
PMID: 39598746
As some previously reported studies have proven that amodiaquine, in addition to its primary antimalarial activity, also has potential for new applications such as the inhibition of cholinesterases, in our...
4.
Matosevic A, Bartolic M, Marakovic N, Zandona A, Petric R, Opsenica D, et al.
Bioorg Med Chem Lett
. 2024 Aug;
112:129928.
PMID: 39151660
Alzheimer's disease is age-related multifactorial neurodegenerative disease manifested by gradual loss of memory, cognitive decline and changes in personality. Due to rapid and continuous growth of its prevalence, the treatment...
5.
Matosevic A, Opsenica D, Spasic M, Marakovic N, Zandona A, Zunec S, et al.
Chem Biol Interact
. 2023 Jul;
382:110620.
PMID: 37406982
The most successful therapeutic strategy in the treatment of Alzheimer's disease (AD) is directed toward increasing levels of the neurotransmitter acetylcholine (ACh) by inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE),...
6.
Matosevic A, Knezevic A, Zandona A, Marakovic N, Kovarik Z, Bosak A
Pharmaceuticals (Basel)
. 2022 Oct;
15(10).
PMID: 36297332
As butyrylcholinesterase (BChE) plays a role in the progression of symptoms and pathophysiology of Alzheimer's disease (AD), selective inhibition of BChE over acetylcholinesterase (AChE) can represent a promising pathway in...
7.
Ramic A, Matosevic A, Debanic B, Mikelic A, Primozic I, Bosak A, et al.
Pharmaceuticals (Basel)
. 2022 Oct;
15(10).
PMID: 36297327
A series of 46 alkaloid derivatives that differ in positions of fluorine atom(s) in the molecule were synthesized and tested as human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors. All tested...
8.
Komatovic K, Matosevic A, Terzic-Jovanovic N, Zunec S, Segan S, Zlatovic M, et al.
Pharmaceutics
. 2022 Jun;
14(6).
PMID: 35745878
Considering that acetylcholinesterase (AChE) inhibition is the most important mode of action expected of a potential drug used for the treatment of symptoms of Alzheimer's disease (AD), our previous pilot...
9.
Matosevic A, Kastelic A, Mikelic A, Zandona A, Katalinic M, Primozic I, et al.
Pharmaceutics
. 2021 Apr;
13(3).
PMID: 33804719
The treatment of central nervous system (CNS) diseases related to the decrease of neurotransmitter acetylcholine in neurons is based on compounds that prevent or disrupt the action of acetylcholinesterase and...
10.
Matosevic A, Bosak A
Arh Hig Rada Toksikol
. 2021 Jan;
71(4):285-299.
PMID: 33410773
Due to their very good chemical and proteolytic stability, ability to penetrate cell membranes, and resemblance to a peptide bond, carbamate derivatives have received much attention in recent years and...